Association between CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System.

MLA

Go, Makiko, et al. “Association between CDK4/6 Inhibitors and Drug‐related Osteonecrosis of the Jaw: A Pharmacoepidemiological Study Using the FDA Adverse Events Reporting System.” International Journal of Cancer, vol. 155, no. 5, Sept. 2024, pp. 849–53. EBSCOhost, https://doi.org/10.1002/ijc.34962.

APA

Go, M., Noguchi, Y., Masuda, R., Asano, H., Kimura, M., Usami, E., & Yoshimura, T. (2024). Association between CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System. International Journal of Cancer, 155(5), 849–853. https://doi.org/10.1002/ijc.34962

Chicago

Go, Makiko, Yoshihiro Noguchi, Rikuto Masuda, Hiroki Asano, Michio Kimura, Eiseki Usami, and Tomoaki Yoshimura. 2024. “Association between CDK4/6 Inhibitors and Drug‐related Osteonecrosis of the Jaw: A Pharmacoepidemiological Study Using the FDA Adverse Events Reporting System.” International Journal of Cancer 155 (5): 849–53. doi:10.1002/ijc.34962.